Related Experiment Video
Updated: Feb 13, 2026

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
Published on: June 16, 2023
KCa3.1 ion channel: A novel therapeutic target for corneal fibrosis
Govindaraj Anumanthan1,2, Suneel Gupta1,2, Michael K Fink1,2
1Harry S. Truman Memorial Veteran Hospital, Columbia, Missouri, United States of America.
Abstract:
Vision impairment from corneal fibrosis is a common consequence of irregular corneal wound healing after injury. Intermediate-conductance calmodulin/calcium-activated K+ channels 3.1 (KCa3.1) play an important role in cell cycle progression and cellular proliferation. Proliferation and differentiation of corneal fibroblasts to myofibroblasts can lead to corneal fibrosis after injury. KCa3.1 has been shown in many non-ocular tissues to promote fibrosis, but its role in corneal fibrosis is still unknown. In this study, we characterized the expression KCa3.1 in the human cornea and its role in corneal wound healing in vivo using a KCa3.1 knockout (KCa3.1-/-) mouse model. Additionally, we tested the hypothesis that blockade of KCa3.1 by a selective KCa3.1 inhibitor, TRAM-34, could augment a novel interventional approach for controlling corneal fibrosis in our established in vitro model of corneal fibrosis. The expression of KCa3.1 gene and protein was analyzed in human and murine corneas. Primary human corneal fibroblast (HCF) cultures were used to examine the potential of TRAM-34 in treating corneal fibrosis by measuring levels of pro-fibrotic genes, proteins, and cellular migration using real-time quantitative qPCR, Western blotting, and scratch assay, respectively. Cytotoxicity of TRAM-34 was tested with trypan blue assay, and pro-fibrotic marker expression was tested in KCa3.1-/-. Expression of KCa3.1 mRNA and protein was detected in all three layers of the human cornea. The KCa3.1-/- mice demonstrated significantly reduced corneal fibrosis and expression of pro-fibrotic marker genes such as collagen I and α-smooth muscle actin (α-SMA), suggesting that KCa3.1 plays an important role corneal wound healing in vivo. Pharmacological treatment with TRAM-34 significantly attenuated corneal fibrosis in vitro, as demonstrated in HCFs by the inhibition TGFβ-mediated transcription of pro-fibrotic collagen I mRNA and α-SMA mRNA and protein expression (p<0.001). No evidence of cytotoxicity was observed. Our study suggests that KCa3.1 regulates corneal wound healing and that blockade of KCa3.1 by TRAM-34 offers a potential therapeutic strategy for developing therapies to cure corneal fibrosis in vivo.
Insights
Blocking the KCa3.1 channel with TRAM-34 reduces corneal fibrosis. This channel is crucial for corneal wound healing and fibrosis development, offering a new therapeutic target for vision impairment.
Area of Science:
- Ophthalmology and Vision Science
- Cell Biology
- Pharmacology
Background:
- Corneal fibrosis, a leading cause of vision impairment, results from abnormal wound healing.
- Intermediate-conductance calmodulin/calcium-activated K+ channels 3.1 (KCa3.1) are implicated in fibrosis in non-ocular tissues but their role in corneal fibrosis is unknown.
- Understanding KCa3.1's role is crucial for developing novel anti-fibrotic therapies for the cornea.
Purpose of the Study:
- To characterize KCa3.1 expression in the human cornea.
- To investigate the role of KCa3.1 in corneal wound healing in vivo using KCa3.1 knockout mice.
- To evaluate the therapeutic potential of KCa3.1 inhibition with TRAM-34 in an in vitro model of corneal fibrosis.
Main Methods:
- KCa3.1 gene and protein expression analysis in human and murine corneas.
- In vitro studies using human corneal fibroblasts (HCFs) treated with TRAM-34, assessing pro-fibrotic markers (qPCR, Western blotting) and cell migration (scratch assay).
- In vivo assessment of corneal fibrosis in KCa3.1 knockout mice and cytotoxicity testing of TRAM-34.
Main Results:
- KCa3.1 expression was detected in all layers of the human cornea.
- KCa3.1 knockout mice exhibited significantly reduced corneal fibrosis and lower expression of pro-fibrotic markers (collagen I, α-SMA).
- TRAM-34 treatment significantly inhibited TGFβ-mediated pro-fibrotic gene and protein expression in HCFs without observed cytotoxicity.
Conclusions:
- KCa3.1 plays a significant role in regulating corneal wound healing and fibrosis.
- Blockade of KCa3.1 by TRAM-34 effectively attenuates corneal fibrosis in vitro.
- KCa3.1 inhibition represents a promising therapeutic strategy for treating corneal fibrosis and preventing vision impairment.
Related Concept Videos
Ion Channels
Ion channels are specialized integral membrane proteins on the plasma membrane that allow...
Non-gated Ion Channels
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
Mechanically-gated Ion Channels
Ligand-gated Ion Channels
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Voltage-gated Ion Channels
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
G-Protein Gated Ion Channels
Sensory...

